**Core Concept**
Edrophonium is a reversible cholinesterase inhibitor used in the diagnosis of myasthenia gravis. It works by competing with acetylcholine for the active site of acetylcholinesterase, thereby increasing the concentration of acetylcholine in the synaptic cleft. Edrophonium's unique mechanism of action allows it to selectively inhibit acetylcholinesterase without affecting other esterases.

**Why the Correct Answer is Right**
Edrophonium binds to the anionic site of acetylcholinesterase, which is a negatively charged region that attracts positively charged acetylcholine molecules. This binding prevents acetylcholinesterase from hydrolyzing acetylcholine, thereby increasing acetylcholine's availability for neurotransmission. The anionic site is distinct from the esteric site, where other cholinesterase inhibitors like neostigmine bind. Edrophonium's specificity for the anionic site allows it to selectively inhibit acetylcholinesterase, making it a useful diagnostic tool.

**Why Each Wrong Option is Incorrect**
**Option B:** The esteric site is where acetylcholinesterase hydrolyzes acetylcholine, and edrophonium does not bind here. Other cholinesterase inhibitors like neostigmine bind to the esteric site, but edrophonium's mechanism is distinct.
**Option C:** Edrophonium does not bind to both sites; its specificity for the anionic site is what sets it apart from other cholinesterase inhibitors.
**Option D:** Edrophonium does bind to a site on acetylcholinesterase; the anionic site is its specific binding location.

**Clinical Pearl / High-Yield Fact**
Edrophonium's rapid onset and short duration of action make it an ideal diagnostic agent for myasthenia gravis, allowing clinicians to assess the efficacy of cholinesterase inhibition in real-time.

**✓ Correct Answer: A. Anionic site**